Product Details

Emend

Aprepitant
80 mg
Capsule


DIN/PIN/NPN

02298791

Manufacturer

Merck Canada Inc.

Formulary Listing Date

2023-01-31  

Unit Price

35.3082

Amount MOH Pays

35.3082

Coverage Status

Exceptional Access Program Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

A04AD12

Interchangeable Products

NO  

LU Clinical Criteria

NO  

EAP Criteria

Therapeutic Class Reimbursement Criteria
Oncology – Supportive Management

Aprepitant

  • Brand(s): Emend
  • Dosage Form/Strength: 80 mg, 125 mg capsule, Tri-pack

Effective September 25, 2014, Emend transitioned to the ODB formulary for reimbursement in patients who meet the Limited Use criteria. Dosage regimens not meeting the LU criteria may be submitted to the EAP for consideration of reimbursement.

EAP Drug Request Form:

Standard Form for EAP Drug Requests

Product Monograph

View Monograph